Both APOA1 and APOA2 are discussed as biomarkers and treatment targets in diabetic retinopathy (DR), polypoidal choroidal vasculopathy (PCV), and AMD, although there is no consistency in studies regarding the mechanism of action [48,49,50,51]. This evidence concerns the gene APOA2 and Polypoidal choroidal vasculopathy.